Ascletis Pharma (歌礼制药) IPO: Valuation Not Justified by Ganovo and Ravidasvir NPV (Part 3)
Corrigenda: There is an error in this insight, please note the correction. Correction: The drug name Conbercept has been misspelt as...
1.1k Views
Ascletis Pharma (1672 HK) IPO: First in Line
Ascletis Pharma is the first pharmaceutical company to file for an IPO in Hong Kong after the government allowed pre-revenue biotech companies to...
912 Views
Ascletis Pharma (歌礼制药) IPO: Three Valuation Risk Factors (Part 2)
In our last Insight covering Ascletis Pharma (Ascletis Pharma (歌礼制药) IPO: Emerging Player in the Crowded HCV Drug Market ), we discuss the...
695 Views
Ascletis Pharma IPO Preview: Drug-Fuelled Euphoria Needed to Justify Valuation
Ascletis Pharma Inc (AP HK) which specialises in developing drugs to treat HCV (hepatitis C virus), HIV and liver cancer, is the first pre-profit...
914 Views
Ascletis Pharma (歌礼制药) IPO: Emerging Player in the Crowded HCV Drug Market
Ascletis Pharma, a China-based biotechnology company, is raising up to USD 300 million to listing on the Hong Kong Stock Exchange. Ascletis is the...
748 Views